Compositions and methods for inhibiting arginase activity
The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
1. A crystalline compound, wherein the compound has the structure of formula (I):
or a pharmaceutically acceptable salt thereof;
wherein:
R 1 is methyl; and
R 4 is (C 1 -C 6 )alkyl.
2. The crystalline compound of claim 1 , which has a purity level of greater than 96% by weight.
3. The crystalline compound of claim 1 having the following structure:
or a pharmaceutically acceptable salt thereof.
4. The crystalline compound of claim 3 , which has a purity level of greater than 96% by weight.
5. The crystalline compound of claim 3 , which has a purity level of greater than 98% by weight.
6. The crystalline compound of claim 3 , which has a purity level of greater than 99.5% by weight.
7. The crystalline compound of claim 3 , characterized by a dynamic vapor sorption (DVS) profile shown in FIG. 7 .
8. The crystalline compound of claim 3 , characterized by a DVS profile with a weight gain of less than 5% of the total weight measured when the relative humidity is increased from 0% to 60% at a constant temperature of 25° C.
9. The crystalline compound of claim 3 , characterized by a DVS profile with a weight gain of less than 1% of the total weight measured when the relative humidity is increased from 0% to 60% at a constant temperature of 25° C.
10. The crystalline compound of claim 3 , which is between 5% and 50% less hygroscopic than its free boronic ester counterpart when measured by DVS.
11. The crystalline compound of claim 3 , which is between 20% and 40% less hygroscopic than its free boronic ester counterpart when measured by DVS.
12. The crystalline compound of claim 3 , which takes up less than 50% of the water than its free boronic ester counterpart when exposed to an environment of 50% humidity for at least 24 hours.
13. The crystalline compound of claim 3 , which takes up less than 25% of the water than its free boronic ester counterpart when exposed to an environment of 50% humidity for at least 24 hours.
14. The crystalline compound of claim 3 , which takes up less than 10% of the water than its free boronic ester counterpart when exposed to an environment of 50% humidity for at least 24 hours.
15. The crystalline compound of claim 3 , which takes up less than 5% of the water than its free boronic ester counterpart when exposed to an environment of 50% humidity for at least 24 hours.
16. The crystalline compound of claim 1 having the following structure:
or a pharmaceutically acceptable salt thereof.
17. A pharmaceutical composition comprising the crystalline compound of claim 1 and a pharmaceutically acceptable carrier.
18. A pharmaceutical composition comprising the crystalline compound of claim 3 and a pharmaceutically acceptable carrier.
19. A pharmaceutical composition comprising the crystalline compound of claim 16 and a pharmaceutically acceptable carrier.
20. A process of making the crystalline compound of claim 1 ,
(i) adding a compound of formula (II)
or a pharmaceutically acceptable salt thereof to a (C 1 -C 6 )alcohol to form a mixture;
(ii) heating the mixture to dissolve the compound of formula (II) or pharmaceutically acceptable salt thereof in the (C 1 -C 6 )alcohol;
(iii) distilling the (C 1 -C 6 )alcohol;
(iv) cooling the mixture; and
(v) isolating the crystalline compound of claim 1 .
21. The process of claim 20 , wherein the (C 1 -C 6 )alcohol is ethanol.
22. The process of claim 20 , wherein the (C 1 -C 6 )alcohol is anhydrous.
23. The process of claim 22 , wherein the (C 1 -C 6 )alcohol is ethanol.